Breast Cancer

Marketing applications submitted for Femara, a post-tamoxifen treatment

Published in Drug Week, June 11th, 2004

Novartis has submitted marketing applications in the United States, European Union, and Switzerland for the use of Femara (letrozole tablets) in the extended adjuvant treatment of early breast cancer in postmenopausal women who have completed standard adjuvant (postsurgery) tamoxifen therapy and remained disease free.

These submissions mark the first time that health authorities will review data on a breast cancer therapy for use following treatment with tamoxifen in the extended adjuvant setting.

The filings comprise results of the independent landmark MA-17 study, which were published expeditiously by the New England Journal of Medicine in...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2004-06-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry